The go-to option for histological support in drug development queries

Medetect is a full-service contract research organisation (CRO) within histology with unique competence in immunopathology, computerised quantitative image analysis and histological research. The company has successfully contributed to crucial histology-based research in a vast number of projects in the pharmaceutical industry over the last 15 years.

International pharmaceutical drug developers often regard Medetect as a preferred partner for drug target assessments. In fact, some of the world's leading pharmaceutical companies rely on Medetect to validate targets by visualising and confirming its presence and importance in human diseased tissues using high-end multiplex immune staining technology. Why do they search all over the world to locate this service? The answer is simple. There are not many companies that can deliver the combination of cutting-edge histology, image analysis together with scientific and strategic consultancy.

“Most of our clients are large, international drug developers. They bring their projects to us mainly thanks to our in-house developed visualisation technology and scientific excellence. On top of that, we also have collaborations with clinical researchers within the Medicon Valley region, and internationally, which enables us to study patient data and tissue samples. By joining forces also with the pharmaceutical industry, we have the power to gain critical new understanding of complex disease mechanisms and contribute to the development of new and better, and individual, treatments for the patients”, explains Professor Jonas Erjefält, Founder of Medetect and Professor at Lund University.

Pioneering technology

To support clients and collaborators, Medetect has built up a well-equipped laboratory and a histological technical platform that, apart from state-of-the-art methods include a pioneering proprietary technique for high-end multiplex staining. Medetect’s method allows for simultaneous detection of all major cell populations together with molecular targets of interest. All information is digitalised and the “histomic” data is processed by own software to yield quantitative information regarding how molecular pathways is expressed in relation to immune cell patterns, tissue damage, and clinical data. The approach can be applied on any human tissues as well as preclinical in vivo or cell culture models.

Strengthening collaborations

Medetect was founded in 2008 as a start-up company at the Smile Life Science Incubator in Medicon Village, Lund. Today, Professor Erjefält’s company is an alumni, but still resides at Smile as it is a vibrant and creative environment for a company like Medetect.

“Due to our location, we can maintain strong relationships with clinical and academic research partners in Lund and the Medicon Valley and enable new research paths within our area”, says Jonas Erjefält.

The collaborations extend further than that and often involve international researchers, including collaborators outside Medicon Valley. This is also the main strategy when Medetect needs to expand the team in Lund, to look to the existing partnerships to recruit like-minded researchers.

SUGGESTED LEGENDS

Välj ni text till bilden vid dörren – är Jonas Erjefält, CEO

Andra färgglada bilden är ett exempel från ett vävnadssnitt där immuncellsmönster kodats av med vår multiplexteknik. Legend in eng kan vara:

Quantitative decoding of immune cell patterns by Medetect´s high-end multiplex staining technique, exemplified here is a patient sample of lymphoid tissue.

or

Patient sample of lymphoid tissue exemplifying visualisation and quantitative decoding of immune cell patterns by Medetect´s high-end multiplex staining technique.